Clinical trial of nimodipine combined with acarbose in the treatment of patients with diabetic peripheral neuropathy
10.13699/j.cnki.1001-6821.2018.06.004
- VernacularTitle:尼莫地平联合阿卡波糖治疗糖尿病周围神经病变的临床研究
- Author:
Lan-Xiang HE
1
;
Li-Qiang JI
;
Jian ZHENG
;
Yan-Bin ZHANG
;
Min GE
Author Information
1. 杭州市余杭区第一人民医院药剂科
- Keywords:
nimodipine;
acarbose;
diabetic peripheral neuropathy;
nerve conduction velocity;
nerve-related growth factor
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(6):622-625
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of nimodipine and acarbose in the treatment of patients with diabetic peripheral neuropathy and its effect on nerve conduction velocity and nerve-related growth factor.Methods Seventy-six patients with diabetic peripheral neuropathy were randomly divided into treatment group and control group,38 cases in each group.Patients in control group were given nimodipine 40 mg,three times a day.On the basis of control group,treatment group was given acarbose 50 mg,three times a day.All patients were treated for a month.The clinical efficacy,nerve conduction velocity,nerve-related growth factor and adverse drug reactions in two groups were compared.Results After treatment,the total effective rates in treatment group and control group were 89.47％ (34 cases/38 cases) and 60.53％ (23 cases/38 cases),with significant difference(P ＜0.05).After treatment,the nerves peroneus communis,median nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) in treatment group were (45.88 ±4.06),(51.69 ±4.56),(44.12 ±4.09) and (46.29 ± 5.71) m · s-1,had significant difference with those in control group,which were (41.16 ±3.83),(44.98 ±4.46),(39.52 ±3.19) and (43.13 ± 4.46) m· s-1 (all P ＜ 0.05).The levels of free fatty acid (FFA),tumor necrosis factor-α (TNF-α) and myelin basic protein (MBP) in treatment group were (471.45±44.28)μmol·L-1,(11.15 ± 1.18) pg · mL-1 and (1.90 ±0.14) μg · L-1,had significant difference with those in control group,which were (542.79 ±46.68) μmol ·L-1,(18.21 ±1.92) pg· mL-1 and (3.41 ±0.38) μg · L-1(all P＜0.05).The levels of vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF) in treatment group were (943.39 ±97.85) and (4.87 ±0.58) ng· L-1,had significant difference with those in control group,which were (755.94 ±70.11) and (3.09 ±0.26) ng · L-1 (all P ＜0.05).The adverse drug reactions in treatment group were 1 case of diarrhea,3 cases of abdominal distension,with the incidence of 10.53％ (4 cases/38 cases).There were 1 case of mild dizziness,2 cases of digestive tract reaction,2 cases of bloating and mild abdominal discom fort in control group,with the incidence of 13.16％ (5 cases/38 cases).There was no significant difference in the incidence of adverse drug reactions between the two groups (P ＞ 0.05).Conclusion Nimodipine combined with acarbose in the treatment of diabetic peripheral neuropathy can effectively improve the nerve conduction velocity and nerve -related growth factor,and the clinical effect is good with high safety.
